SlideShare uma empresa Scribd logo
1 de 22
Baixar para ler offline
Vaccines






Vaccination is the phenomenon of preventive
immunization.
Vaccination involves the administration(oral or
injection) of an antigen to elicit an antibody
response that will protect the organism against
future infections.
History of vaccinia --- the cow pox viruses
inoculated by Jenner, stimulate the body’s
immune system to produce antibodies which
neutralize the cow pox as well as small pox
viruses. (small pox- virulent disease).
1.
2.
3.

Dead bacteria or inactivated viruses.
Live non virulent or weakened (attenuated)
bacteria/ or viruses.
Viral fragments or bacterial molecules
(subunit vaccines).
1.

2.

3.

Subunit R.V : These are components of the
pathogenic organisms. They include
proteins, peptides and DNA.
Attenuated R.V: These are genetically
modified pathogenic organisms (bacteria or
viruses) that are made non- pathogenic and
are used as vaccines.
Vector R.V : These are the genetically
modified viral vectors that can be used as
vaccines against certain pathogens.
Components of pathogenic organism’s proteins, peptides and DNA.
Eg: Hepatitis B vaccine.
 While proteins must be produced in a
cellular environment, peptides can be
synthesized.
 However, peptides are often only weakly
immunogenic.
 For this reason, a mixture of peptides may
be utilized, although whole recombinant
proteins are most often used.

Advantages
 Purity in preparation.
 Stability
 Safe use
Disadvantages
 High cost factor
 Possible alteration in native conformation








Primarily affects liver causing chronic
hepatitis, cirrhosis and liver cancer.
Hepatitis B virus is a 42nm particle, called
Dane particle.
Consists of a core containing viral genome
(DNA) surrounded by a phospholipid
envelope carrying surface antigens.
The gene encoding for hepatitis B surface
antigen (HBsAg) has been identified.




Recombinant hepatitis B vaccine as a subunit
vaccine, is produced by cloning HbsAg gene
in yeast cells.
Saccharomyces cerevisiae, a harmless baking
and brewing yeast, is used for this purpose.
1.

2.
3.
4.
5.

6.

The gene foe HbsAg is inserted (pMA 56) which is
linked to the alcohol dehydrogenase promoter.
These plasmids are then transferred and cultured.
The cells grown in tryptophan, free medium are
selected and cloned.
The yeast cells are cultured.
The HbsAg gene is expressed to produce 2nm sized
particles similar to those found in patients infected
with hepatits B. (these particles are immunoreactive
with anti- HbsAg antibodies)
The subunit HbsAg as 22nm particles can be
isolated and used to immunize individuals against
hepatits B.
These are genetically modified pathogenic
organisms (bacteria or viruses) that are made
non- pathogenic and are used as vaccines.
 The genetic manipulations for the production
of these vaccines are broadly of 2 types:
1. Deletion or modification of virulence genes of
the pathogenic organisms.
2. Genetic manipulation of non- pathogenic
organisms to carry and express antigen
determinants from pathogenic organisms.
Eg. Cholera vaccine











Vibrio cholerae

On entering the small intestine, V.cholerae colonises and
starts producing large amounts of toxic protein, a hexameric
enterotoxin.
Currently used cholera vaccine is composed of phenol-killed

V. cholerae.

Enterotoxin, a hexamer, consists of one A subunit and 5
identical B subunits.
The A subunit has 2 functional domains- the A1 peptide
which possesses the toxic activity and A2 peptide that joins A
subunits to B subunits.
By genetic engg, it was possible to delete the DNA sequence
encoding A1 peptide that joins A subunit to B subunits.
By genetic engg., it was possible to delete the DNA sequence
encoding A1 peptide and create a new strain of V. cholerae.
1.

2.

A tertracycline resistance gene was inserted into the
A1 peptide sequence of V.cholerae chromosome. This
destroys the DNA sequence encoding for A1 peptide,
besides making the strain resistant to tetracycline.
Unfortunately, the tetracycline resistant gene is easily
lost and the enterotoxin activity is restored. Because of
this, the new strain of V.cholerae as such cannot be
used as a vaccine.
The DNA sequence of A1 peptide is incorporated into
the plasmid, cloned and digested with restriction
enzymes (Cla1 and Xba1). In this manner, the A1
peptide coding sequence is deleted (the DNA encoding
for 183 of the 194 amino acids of the A1 peptide is
actually removed. By using T4 DNA ligase, the plasmid
is recircularized. This plasmid contains a small portion
of A1 peptide coding sequence.
3. The plasmid, containing the deleted A1 peptide
sequence is transferred by conjugation into the V.
cholerae strain carrying a tetracycline resistance gene.
4. Recombination can occur b/w the plasmid (containing a
small portion of peptide A1 coding sequence) and the
chromosome of V. cholerae (carrying tetracycline
resistance gene). The result of this double crossover is
the formation of V. cholerae containing a chromosomal
DNA lacking A1 peptide DNA sequence. As the
bacterium multiplies, the plasmids are lost in the next
few generations.
5. The V. cholerae cells defective in A1 peptide are
selected, based on tetracycline sensitivity. It may be
noted that this new strain lacks tetracycline resistance
gene.
Advantages
 Immune response is substantially high.
 Stable
Disadvantages
 Side effects









These are the genetically modified viral vectors
that can be used as vaccines against certain
pathogens.
Vaccinia viruse (Jenner)
Genes encoding significant Ag’s from
pathogens may be transferred to attenuated
viruses/bacteria
Vectors include: vaccinia, polio, adenoviruses
Salmonella, BCG strain of M. bovis, oral Strep
Other vectors may prove to be safer.
Vaccinia virus








Contains a double stranded DNA that encodes about
200 different proteins.
The genome of this virus can accommodate stretches of
foreign DNA which can be expressed along with the
viral genes.
It can replicate in the host cell cytoplasm(of the infected
cells) rather than nucleus. [E]
The foreign DNA is under the control of the virus, and is
expressed independantly from the host cell genome.
Harmless, easy to cultivate and stable for years after
lyophilization.
All these features make it strong candidates for vector
vaccine.
Advantages
1. It stimulates B-lymphocytes (to produce
antibodies) and T-lymphocytes (to kill
virus infected cells). [E]. Thus vaccinia can
produce a high level of immunoprotection.
2. Can vaccinate different different
individuals against different diseases
simultaneously. (genes encoding different
antigens)
Procedure
1.








Assembly of plasmid insertion vector:
Fresh vaccinia viruses are processed to release hteir
DNAs.
Now genes from hepatitis B virus, herpes simplex virus
and influenza virus are added one after the other and
inserted into vaccinia virus genome.
These DNA clusters are cloned in E.coli for increasing
their number and to produce plasmid insertion vectors.
The plasmid contains the foreign subunit genes, the
natural vaccinia genes, including the promoter genes.
The recombinant plasmids are isolated and purified
and serve as plasmid insertion vectors.
Procedure
2.









Production of recombinant vaccinia viruses
The animal cells are infected with plasmid insertion vectors and
normal vaccinia viruses.
As the viral replication occurs, the plasmids are taken upto
produce recombinant vaccinia viruses.
The plasmid insertion vector incorporates its gene into vaccinia
virus genome at a place that encodes fot the enzyme thymidine
kinase (TK).
Thus the recombinant viruses have lost their ability to produce TK.
These are 2 advantages of loss of TK gene – one, is that it is easy
to select recombined vaccinia viruses that lack TK gene and the
second, is that these viruses are less infectious than normal
viruses.
The recombinant vaccinia viruses, released from the cultured
animal cells, can be successfully used as vaccines.
Advantages
1.
2.

3.

Authenticated antigens that closely resemble natural
antigens can be produced.
The virus can replicate in the host cells. This enables the
amplification of the antigens for their action on Blymphocytes and T- lymphocytes.
There is a possibility of vaccinating several diseases with
one recombinant vaccinia virus.

Disadvantages
1.
2.

The most important limitation is the yet known risks of
using these vaccines in humans.
There may be serious complications of using recombinant
viral vaccines in immunosuppressed individuals such as
AIDS patients.
Vaccines









It is known that the antigens located on the surface of a bacterial
cell are more immunogenic than the antigens in the cytoplasm.
Based on this observation, scientists have developed strategies to
coat the surfaces of non-pathogenic organisms with antigens of
pathigenic bacteria.
Flagellin is a protein present in the flagella (thread like filaments)of
Salmonella.
A synthetic oligonucleotide encoding the epitope of cholera toxin B
subunit was inserted into Salmonella flagellin gene.
This epitope was in fact found on the flagellum surface.
These flagella engineered bacteria, when administered to
mice, raised antibodies against the cholera B toxin subunit peptide.
It may be possible in future to incorporate multiple epitopes (2 or 3)
into the flagellin gene to create multivalent bacterial vaccines.

Mais conteúdo relacionado

Mais procurados (20)

Vaccines AND THEIR ROLE
Vaccines AND THEIR ROLEVaccines AND THEIR ROLE
Vaccines AND THEIR ROLE
 
New generation vaccines production
New generation vaccines productionNew generation vaccines production
New generation vaccines production
 
AIDS
AIDSAIDS
AIDS
 
Vaccines
VaccinesVaccines
Vaccines
 
vaccine & vaccination.pptx
vaccine & vaccination.pptxvaccine & vaccination.pptx
vaccine & vaccination.pptx
 
Recombinant Vaccines
Recombinant VaccinesRecombinant Vaccines
Recombinant Vaccines
 
Vector vacccine
Vector vacccineVector vacccine
Vector vacccine
 
Viral vaccines, An introduction
Viral vaccines, An introduction Viral vaccines, An introduction
Viral vaccines, An introduction
 
Vaccinology
VaccinologyVaccinology
Vaccinology
 
Subunit and peptide vaccine
Subunit and peptide vaccineSubunit and peptide vaccine
Subunit and peptide vaccine
 
Tumour Viruses
Tumour VirusesTumour Viruses
Tumour Viruses
 
DNA Vaccine
DNA VaccineDNA Vaccine
DNA Vaccine
 
David Haselwood | How vaccines prevent diseases
David Haselwood | How vaccines prevent diseasesDavid Haselwood | How vaccines prevent diseases
David Haselwood | How vaccines prevent diseases
 
HIV Vaccine Development Strategies
HIV Vaccine Development StrategiesHIV Vaccine Development Strategies
HIV Vaccine Development Strategies
 
Vaccine
VaccineVaccine
Vaccine
 
AIDS
AIDSAIDS
AIDS
 
Antiviral
AntiviralAntiviral
Antiviral
 
Hepatitis B Vaccine
Hepatitis B  VaccineHepatitis B  Vaccine
Hepatitis B Vaccine
 
Phage therapy
Phage therapyPhage therapy
Phage therapy
 
Vaccines
VaccinesVaccines
Vaccines
 

Semelhante a Vaccines

Vaccine ppt
Vaccine pptVaccine ppt
Vaccine pptidjf
 
Dna vaccine final ppt
Dna vaccine final pptDna vaccine final ppt
Dna vaccine final pptTaye Desta
 
Vaccines and Type of Vaccines
Vaccines and Type of VaccinesVaccines and Type of Vaccines
Vaccines and Type of VaccinesTathagat Sah
 
recombinant drugs.pdf
recombinant drugs.pdfrecombinant drugs.pdf
recombinant drugs.pdfssuser1703a8
 
BIOTECHNOLOGY 3RD ICA ASSIGNMENT BY ALOK KUMAR.pptx
BIOTECHNOLOGY 3RD ICA ASSIGNMENT BY ALOK KUMAR.pptxBIOTECHNOLOGY 3RD ICA ASSIGNMENT BY ALOK KUMAR.pptx
BIOTECHNOLOGY 3RD ICA ASSIGNMENT BY ALOK KUMAR.pptxAlok Kumar
 
Vaccine Designing
Vaccine DesigningVaccine Designing
Vaccine DesigningMiccrophage
 
Emerging trend in_biotechnology: Recombinant Vaccine technology
Emerging trend in_biotechnology: Recombinant Vaccine technologyEmerging trend in_biotechnology: Recombinant Vaccine technology
Emerging trend in_biotechnology: Recombinant Vaccine technologyArrshathj Jiyaullah
 
Les dossiers d’expertise du Dr Hervé Seligmann, du Prof. Luc Montagnier et du...
Les dossiers d’expertise du Dr Hervé Seligmann, du Prof. Luc Montagnier et du...Les dossiers d’expertise du Dr Hervé Seligmann, du Prof. Luc Montagnier et du...
Les dossiers d’expertise du Dr Hervé Seligmann, du Prof. Luc Montagnier et du...Guy Boulianne
 

Semelhante a Vaccines (20)

Vaccine
VaccineVaccine
Vaccine
 
Vaccine ppt
Vaccine pptVaccine ppt
Vaccine ppt
 
Dna vaccine final ppt
Dna vaccine final pptDna vaccine final ppt
Dna vaccine final ppt
 
Vaccines
VaccinesVaccines
Vaccines
 
Vaccines
VaccinesVaccines
Vaccines
 
R dna seminar
R dna seminarR dna seminar
R dna seminar
 
Vaccine
VaccineVaccine
Vaccine
 
vector vaccines
vector vaccinesvector vaccines
vector vaccines
 
Vaccines and Type of Vaccines
Vaccines and Type of VaccinesVaccines and Type of Vaccines
Vaccines and Type of Vaccines
 
recombinant drugs.pdf
recombinant drugs.pdfrecombinant drugs.pdf
recombinant drugs.pdf
 
BIOTECHNOLOGY 3RD ICA ASSIGNMENT BY ALOK KUMAR.pptx
BIOTECHNOLOGY 3RD ICA ASSIGNMENT BY ALOK KUMAR.pptxBIOTECHNOLOGY 3RD ICA ASSIGNMENT BY ALOK KUMAR.pptx
BIOTECHNOLOGY 3RD ICA ASSIGNMENT BY ALOK KUMAR.pptx
 
Vaccine Designing
Vaccine DesigningVaccine Designing
Vaccine Designing
 
Emerging trend in_biotechnology: Recombinant Vaccine technology
Emerging trend in_biotechnology: Recombinant Vaccine technologyEmerging trend in_biotechnology: Recombinant Vaccine technology
Emerging trend in_biotechnology: Recombinant Vaccine technology
 
Vaccines in biotechnology
Vaccines in biotechnologyVaccines in biotechnology
Vaccines in biotechnology
 
DNA Vaccine.pptx
DNA Vaccine.pptxDNA Vaccine.pptx
DNA Vaccine.pptx
 
Vaccines- and its types
Vaccines- and its typesVaccines- and its types
Vaccines- and its types
 
Immunology ..
Immunology ..Immunology ..
Immunology ..
 
Dna Vaccines
Dna VaccinesDna Vaccines
Dna Vaccines
 
Les dossiers d’expertise du Dr Hervé Seligmann, du Prof. Luc Montagnier et du...
Les dossiers d’expertise du Dr Hervé Seligmann, du Prof. Luc Montagnier et du...Les dossiers d’expertise du Dr Hervé Seligmann, du Prof. Luc Montagnier et du...
Les dossiers d’expertise du Dr Hervé Seligmann, du Prof. Luc Montagnier et du...
 
Vaccine
VaccineVaccine
Vaccine
 

Último

Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 

Último (20)

Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 

Vaccines

  • 2.    Vaccination is the phenomenon of preventive immunization. Vaccination involves the administration(oral or injection) of an antigen to elicit an antibody response that will protect the organism against future infections. History of vaccinia --- the cow pox viruses inoculated by Jenner, stimulate the body’s immune system to produce antibodies which neutralize the cow pox as well as small pox viruses. (small pox- virulent disease).
  • 3. 1. 2. 3. Dead bacteria or inactivated viruses. Live non virulent or weakened (attenuated) bacteria/ or viruses. Viral fragments or bacterial molecules (subunit vaccines).
  • 4. 1. 2. 3. Subunit R.V : These are components of the pathogenic organisms. They include proteins, peptides and DNA. Attenuated R.V: These are genetically modified pathogenic organisms (bacteria or viruses) that are made non- pathogenic and are used as vaccines. Vector R.V : These are the genetically modified viral vectors that can be used as vaccines against certain pathogens.
  • 5. Components of pathogenic organism’s proteins, peptides and DNA. Eg: Hepatitis B vaccine.  While proteins must be produced in a cellular environment, peptides can be synthesized.  However, peptides are often only weakly immunogenic.  For this reason, a mixture of peptides may be utilized, although whole recombinant proteins are most often used. 
  • 6. Advantages  Purity in preparation.  Stability  Safe use Disadvantages  High cost factor  Possible alteration in native conformation
  • 7.     Primarily affects liver causing chronic hepatitis, cirrhosis and liver cancer. Hepatitis B virus is a 42nm particle, called Dane particle. Consists of a core containing viral genome (DNA) surrounded by a phospholipid envelope carrying surface antigens. The gene encoding for hepatitis B surface antigen (HBsAg) has been identified.
  • 8.   Recombinant hepatitis B vaccine as a subunit vaccine, is produced by cloning HbsAg gene in yeast cells. Saccharomyces cerevisiae, a harmless baking and brewing yeast, is used for this purpose.
  • 9. 1. 2. 3. 4. 5. 6. The gene foe HbsAg is inserted (pMA 56) which is linked to the alcohol dehydrogenase promoter. These plasmids are then transferred and cultured. The cells grown in tryptophan, free medium are selected and cloned. The yeast cells are cultured. The HbsAg gene is expressed to produce 2nm sized particles similar to those found in patients infected with hepatits B. (these particles are immunoreactive with anti- HbsAg antibodies) The subunit HbsAg as 22nm particles can be isolated and used to immunize individuals against hepatits B.
  • 10. These are genetically modified pathogenic organisms (bacteria or viruses) that are made non- pathogenic and are used as vaccines.  The genetic manipulations for the production of these vaccines are broadly of 2 types: 1. Deletion or modification of virulence genes of the pathogenic organisms. 2. Genetic manipulation of non- pathogenic organisms to carry and express antigen determinants from pathogenic organisms. Eg. Cholera vaccine 
  • 11.        Vibrio cholerae On entering the small intestine, V.cholerae colonises and starts producing large amounts of toxic protein, a hexameric enterotoxin. Currently used cholera vaccine is composed of phenol-killed V. cholerae. Enterotoxin, a hexamer, consists of one A subunit and 5 identical B subunits. The A subunit has 2 functional domains- the A1 peptide which possesses the toxic activity and A2 peptide that joins A subunits to B subunits. By genetic engg, it was possible to delete the DNA sequence encoding A1 peptide that joins A subunit to B subunits. By genetic engg., it was possible to delete the DNA sequence encoding A1 peptide and create a new strain of V. cholerae.
  • 12. 1. 2. A tertracycline resistance gene was inserted into the A1 peptide sequence of V.cholerae chromosome. This destroys the DNA sequence encoding for A1 peptide, besides making the strain resistant to tetracycline. Unfortunately, the tetracycline resistant gene is easily lost and the enterotoxin activity is restored. Because of this, the new strain of V.cholerae as such cannot be used as a vaccine. The DNA sequence of A1 peptide is incorporated into the plasmid, cloned and digested with restriction enzymes (Cla1 and Xba1). In this manner, the A1 peptide coding sequence is deleted (the DNA encoding for 183 of the 194 amino acids of the A1 peptide is actually removed. By using T4 DNA ligase, the plasmid is recircularized. This plasmid contains a small portion of A1 peptide coding sequence.
  • 13. 3. The plasmid, containing the deleted A1 peptide sequence is transferred by conjugation into the V. cholerae strain carrying a tetracycline resistance gene. 4. Recombination can occur b/w the plasmid (containing a small portion of peptide A1 coding sequence) and the chromosome of V. cholerae (carrying tetracycline resistance gene). The result of this double crossover is the formation of V. cholerae containing a chromosomal DNA lacking A1 peptide DNA sequence. As the bacterium multiplies, the plasmids are lost in the next few generations. 5. The V. cholerae cells defective in A1 peptide are selected, based on tetracycline sensitivity. It may be noted that this new strain lacks tetracycline resistance gene.
  • 14. Advantages  Immune response is substantially high.  Stable Disadvantages  Side effects
  • 15.      These are the genetically modified viral vectors that can be used as vaccines against certain pathogens. Vaccinia viruse (Jenner) Genes encoding significant Ag’s from pathogens may be transferred to attenuated viruses/bacteria Vectors include: vaccinia, polio, adenoviruses Salmonella, BCG strain of M. bovis, oral Strep Other vectors may prove to be safer.
  • 16. Vaccinia virus       Contains a double stranded DNA that encodes about 200 different proteins. The genome of this virus can accommodate stretches of foreign DNA which can be expressed along with the viral genes. It can replicate in the host cell cytoplasm(of the infected cells) rather than nucleus. [E] The foreign DNA is under the control of the virus, and is expressed independantly from the host cell genome. Harmless, easy to cultivate and stable for years after lyophilization. All these features make it strong candidates for vector vaccine.
  • 17. Advantages 1. It stimulates B-lymphocytes (to produce antibodies) and T-lymphocytes (to kill virus infected cells). [E]. Thus vaccinia can produce a high level of immunoprotection. 2. Can vaccinate different different individuals against different diseases simultaneously. (genes encoding different antigens)
  • 18. Procedure 1.      Assembly of plasmid insertion vector: Fresh vaccinia viruses are processed to release hteir DNAs. Now genes from hepatitis B virus, herpes simplex virus and influenza virus are added one after the other and inserted into vaccinia virus genome. These DNA clusters are cloned in E.coli for increasing their number and to produce plasmid insertion vectors. The plasmid contains the foreign subunit genes, the natural vaccinia genes, including the promoter genes. The recombinant plasmids are isolated and purified and serve as plasmid insertion vectors.
  • 19. Procedure 2.       Production of recombinant vaccinia viruses The animal cells are infected with plasmid insertion vectors and normal vaccinia viruses. As the viral replication occurs, the plasmids are taken upto produce recombinant vaccinia viruses. The plasmid insertion vector incorporates its gene into vaccinia virus genome at a place that encodes fot the enzyme thymidine kinase (TK). Thus the recombinant viruses have lost their ability to produce TK. These are 2 advantages of loss of TK gene – one, is that it is easy to select recombined vaccinia viruses that lack TK gene and the second, is that these viruses are less infectious than normal viruses. The recombinant vaccinia viruses, released from the cultured animal cells, can be successfully used as vaccines.
  • 20. Advantages 1. 2. 3. Authenticated antigens that closely resemble natural antigens can be produced. The virus can replicate in the host cells. This enables the amplification of the antigens for their action on Blymphocytes and T- lymphocytes. There is a possibility of vaccinating several diseases with one recombinant vaccinia virus. Disadvantages 1. 2. The most important limitation is the yet known risks of using these vaccines in humans. There may be serious complications of using recombinant viral vaccines in immunosuppressed individuals such as AIDS patients.
  • 22.        It is known that the antigens located on the surface of a bacterial cell are more immunogenic than the antigens in the cytoplasm. Based on this observation, scientists have developed strategies to coat the surfaces of non-pathogenic organisms with antigens of pathigenic bacteria. Flagellin is a protein present in the flagella (thread like filaments)of Salmonella. A synthetic oligonucleotide encoding the epitope of cholera toxin B subunit was inserted into Salmonella flagellin gene. This epitope was in fact found on the flagellum surface. These flagella engineered bacteria, when administered to mice, raised antibodies against the cholera B toxin subunit peptide. It may be possible in future to incorporate multiple epitopes (2 or 3) into the flagellin gene to create multivalent bacterial vaccines.